ImmunityBio (IBRX) is back in focus after an FDA warning letter criticized promotional claims for its cancer drug Anktiva, as well as a wave of securities class action lawsuits that accused executives of overstating the therapy’s capabilities.

Recent trading reflects this mix of good and bad headlines, with the share price at US$7.30 after a 1 month share price return of 18.89% decline, but a very large 3 month share price return and a 1 year total shareholder return of 157.95% showing how quickly sentiment around ImmunityBio has shifted.

If you are weighing ImmunityBio against other biotech names using artificial intelligence in healthcare, it could be a useful moment to scan the market via our screener of 37 healthcare AI stocks

With ImmunityBio now at US$7.30, trading at a large discount to one estimate of intrinsic value and to the average analyst price target, the key question is whether this legal overhang leaves a genuine opportunity or if markets are already pricing in future growth.

Most Popular Narrative: 45.9% Undervalued

With ImmunityBio last closing at $7.30 and the most followed narrative pointing to a fair value of $13.50, the gap between story and price is hard to ignore.

The rapid global expansion of ANKTIVA into 33 countries, including the U.S., EU, U.K., and Saudi Arabia, together with commercial partners like Accord and regional distributors, sets up a much larger treated patient base over time, which is directly tied to future product revenue growth.

Want to see what kind of revenue trajectory and margin shift sit behind that fair value gap? The narrative leans on aggressive top line growth, a sharp swing into profitability, and a future earnings multiple usually reserved for premium growth names.

Result: Fair Value of $13.50 (UNDERVALUED)

However, this story only holds if ANKTIVA actually wins approvals beyond bladder cancer and if broader global adoption matches expectations instead of stalling.

Next Steps

The mix of legal risk, growth expectations and valuation gaps makes this a complex setup, so move quickly to review the data and weigh both 2 key rewards and 4 important warning signs

Looking for more investment ideas?

If ImmunityBio has your attention, do not stop here. Widen your watchlist with a few focused stock ideas that could sharpen your next move.

• Target income potential by reviewing companies offering resilient payouts in the 12 dividend fortresses
• Hunt for quality at a discount by scanning companies that combine strong fundamentals with attractive pricing in the 62 high quality undervalued stocks
• Prioritize capital preservation by checking businesses screened for stability and lower risk profiles in the 67 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.